© 2026 Sinochem Nanjing Corporation,
All Right Reserved
The road to rifabutin started with hungry microbiologists searching for better ways to fight tuberculosis and other mycobacterial infections. When rifampicin hit the market in the 1960s, it felt revolutionary for tuberculosis therapy, but problems soon appeared. High-dose rifampicin often triggered side effects or lost punch in the face of drug-resistant strains. Scientists at the Italian company Lepetit charted new territory and synthesized rifabutin—a derivative with a slightly tweaked backbone—in the 1970s. They wanted something more active against atypical mycobacteria, including those behind infections in people with compromised immune systems. By the 1980s, studies pointed to rifabutin’s ability to battle Mycobacterium avium complex (MAC), especially in HIV-positive patients. In a world caught off guard by emerging drug resistance and HIV’s rapid spread, rifabutin arrived just in time to plug a critical gap.
Rifabutin’s orange-brown crystals jump out in any lab setup. Sold mostly as capsules, with each pill typically packing either 150 or 300 milligrams, companies have developed several brands—Mycobutin among the most recognizable. Beyond pills, investigators in specialized research settings have looked into injectable forms or powder mixes, although these haven’t taken hold in the mainstream. Pharmacies across the world keep rifabutin on the shelf as a key weapon against MAC, and sometimes for ‘off-label’ use against other tough mycobacterial infections that simply won’t back down.
Structurally, rifabutin is not far from its cousin, rifampicin, but brings its own quirks. Its molecular formula, C46H62N4O16, signals a hefty compound, and its molecular weight hits the scales at roughly 847.0 g/mol. It dissolves easily in dimethyl sulfoxide (DMSO), chloroform, and methanol, but water doesn’t break it down well. Heat and light speed up its degradation, so it needs to stay tucked away in a cool, dark spot. The compound’s color almost screams caution: the orange-red pigment is notorious for staining—not just laboratory surfaces, but also body fluids like urine and sweat during treatment.
Manufacturers list rifabutin’s purity levels, which usually top 98% by high-performance liquid chromatography (HPLC) analysis. The U.S. FDA and EMA tightly control how this drug should be labeled. Each batch must state not just the dosage but also the expiration date, storage recommendations (such as store at 20-25°C, protected from excess light), and proper identification codes. Labels highlight potential allergens and stress that only licensed professionals should prescribe this product. Every vial or capsule batch gets batch numbers for traceability—a lesson learned from decades of adverse events tracing back, sometimes, to manufacturing slips.
Producing rifabutin starts with fermenting Streptomyces mediterranei to grow rifamycin B, the parent structure. Chemists then subject that precursor to semi-synthetic tricks, including treatment with various reagents to open and rearrange certain rings in the structure. Methylation and other modifications carve out the features that set rifabutin apart. This process calls for precision—small shifts throw off the antibiotic’s activity or toxicity. Filtration and purification steps follow, cutting out impurities or unwanted side products. By the end, operators verify the product’s key features using spectroscopic techniques like NMR and mass spectrometry to ensure each batch meets medical-grade criteria.
Chemists haven’t stood still since rifabutin’s first patent. Researchers have played with functional groups on the molecule’s ansa bridge and naphthohydroquinone core to squeeze out better solubility, potency, or safety. Some groups have replaced certain methyl groups with larger or smaller atoms, aiming to tune the antibiotic’s affinity for bacterial RNA polymerase. Reductive and oxidative processes help introduce new rings or oxidize functional regions for analogs. Others tinker at the periphery, hoping to outflank resistance by staying a step ahead of bacterial mutations—an arms race that doesn’t pause for anyone.
Rifabutin’s chemical tags trace through patent filings, scientific papers, and marketplace shelves. Systematic names like “(9S,12S,14Z,15E,17S,18S,19S,20R,21S,22R,23E,25E,27E,29E,31S,32S,34aS)-6,7,8,9,12,13,14,15,16,17...” (you get the idea—it’s a mouthful) show up in regulatory files. Common synonyms run from LM 427 to Ansamycin LM427, but clinicians and patients mostly know the product as Mycobutin, or simply ‘rifabutin capsules.’ Trade brands may differ slightly depending on the region, but every label ties back to the same core structure.
Federally approved rifabutin must pass strict quality tests to prevent contamination with endotoxins, solvents, or microbial byproducts. Hospitals and pharmacies require tight controls on how the product is stored, measured, and dispensed. Nursing and pharmacy staff wear gloves when handling open capsules to avoid accidental staining or exposure, as rifabutin’s pigment marks more than just test tubes. Anyone preparing bulk solutions and investigational forms follows OSHA’s hazardous drug protocols, including working in ventilated hoods. Disposal practices treat this drug as potentially hazardous waste, reflecting lessons learned from decades of antibiotic stewardship and hazardous spill management.
Rifabutin found its place treating mycobacterial infections, mostly MAC in patients wrestling with HIV/AIDS. Its broad spectrum covers a slew of other non-tuberculous mycobacteria, and doctors have turned to it when tuberculosis flares up with resistance to first-line drugs. Immunocompromised people—solid organ transplant recipients, those with leukemia or lymphoma—benefit from rifabutin’s unique profile, which lets it play nice with many antiretrovirals. It helps keep mycobacterial bugs in check where weaker drugs struggle, offering a lifeline when stakes are high. Offices that treat TB have it in the tool kit for outpatient management, especially if rifampicin can’t be used due to side effects or dangerous drug interactions.
Academic centers and pharmaceutical companies both keep rifabutin under the microscope. They investigate ways to sharpen its activity, limit resistance, and improve patient outcomes. Some labs try to join rifabutin with nano-carriers that promise steadier blood levels or better delivery to infected tissues. Others test combination regimens with newer antibiotics, hunting for partners that can outfox resistant strains. Investments in automated screening let researchers cycle through thousands of derivatives in search of the next breakthrough. Big data and machine learning point chemists toward tweaks that might give the drug more punch or strip out harmful side effects—a strategy that never loses relevance as antibiotic resistance surges worldwide.
While rifabutin works wonders for many, it isn’t free from trouble. Some users develop uveitis—a painful inflammation of the eye—especially when rifabutin doses climb too high alongside certain HIV therapies like clarithromycin or protease inhibitors. Color changes in urine, tears, or sweat rarely trigger concern but can alarm patients just starting therapy. Some experience bone marrow suppression, leading to manual blood count checks throughout the course. Animal tests and long-term studies in humans flag possible but rare risks of liver injury or hypersensitivity. Regulators and drug labels highlight these issues, and prescribers check for interactions with warfarin, oral contraceptives, and antifungal drugs, which can spiral into problems if ignored.
Looking ahead, the story of rifabutin is far from over. MDR-TB and XDR-TB still plague health systems, and drugs like rifabutin offer much-needed ammunition. Research into analogs, prodrugs, and improved formulations could reclaim ground lost to resistance. Approaches that tie rifabutin into combination pills or tailor it with smart drug-delivery techniques have the best shot at keeping it relevant. Public health leaders know the price of ignoring antibiotic innovation; without steady investment and novel products, there’s real risk of sliding backward. Rifabutin’s journey—from a lab oddity to a critical therapy—underscores what persistence and creativity can offer in the fight against infectious disease.
Rifabutin doesn’t show up in medicine cabinets for everyday sniffles, but when it does, doctors and patients know they’re up against a stubborn foe. This antibiotic gets called into action most often for people living with HIV, especially if they end up with a mycobacterial infection. Mycobacterium avium complex (MAC) shows up in these patients once the immune system drops its guard. Rifabutin helps keep MAC from taking hold, so people with compromised immune systems have less to worry about. The drug’s ability to block the bacteria’s ability to multiply buys time for the body and for other medicines to work.
Plenty of antibiotics crowd pharmacy shelves, so it’s fair to wonder why doctors lean on Rifabutin in tricky cases. The challenge with tuberculosis (TB) treatment often centers on drug interactions. People who take antiretroviral therapy for HIV bump into problems with classic drugs like rifampin. Rifabutin sidesteps some of those issues, thanks to differences in how the liver processes each medicine. It causes fewer ripples with HIV drugs, making it safer for those managing both infections.
A study published in the journal Clinical Infectious Diseases showed that adding Rifabutin for MAC prevention reduced the risk of infection by over half compared to a placebo. Not a perfect solution, but a solid help for people facing a tough set of health challenges. The World Health Organization recognizes Rifabutin as a safe option for those who can’t use other medicines because of interactions or side effects.
People taking Rifabutin might notice reddish-orange urine, tears, or sweat. It looks alarming at first, but it’s just a side effect of the drug breaking down in the body. Some folks end up dealing with stomach pain or rashes, yet many handle the course just fine with a little support from their care team. In my own experience working with patients on complex antibiotic regimens, trust and good communication make a world of difference. Patients do better once they know what to expect and feel comfortable speaking up about side effects.
Access remains an issue in regions battling multidrug-resistant TB. Rifabutin costs more than other drugs in its class. Some national programs struggle to stock and distribute it. Back when I volunteered with a global health team, we saw the need for partnerships between governments, non-profits, and pharmaceutical companies to bridge gaps in supply. Education comes next. Health workers in remote clinics need training to spot the cases where Rifabutin brings the most benefit and how to screen for complications quickly.
The science behind Rifabutin moves forward each year. Research teams keep hunting for better dosing strategies and ways to cut down on interactions with other medicines. Digital health records now flag potential problems earlier, and pharmacists can catch risky combinations before they turn dangerous. These small changes add up, leading to safer care and better outcomes.
Infectious disease care boils down to timing and smart choices, and Rifabutin has carved out a spot for itself by making life a little more manageable for some of the sickest patients. Success depends on placing people at the center, building access, and sharing knowledge from the clinic to the community level. The story of Rifabutin says a lot about persistence, teamwork, and science coming together where it counts.
Rifabutin comes up a lot in the fight against infections, especially for folks dealing with tuberculosis and for those living with HIV who might get certain tough-to-treat bacterial infections. Doctors know this drug works well, but nobody wants to end up trading one problem for a whole new set of troubles. In my time talking with people managing these tough diagnoses, I’ve noticed side effects from medicines like rifabutin often become almost as big a deal as the main illness itself.
Most people I’ve talked with mention changes they didn’t expect after starting rifabutin. One of the first things they notice? Their urine and sweat can pick up an orange tint. It looks alarming the first time, but it doesn’t harm anything by itself. Nausea and stomach pain also come up time and again. In clinics, folks bring ginger or crackers along, hoping to calm down their queasy stomachs so they can stick with the treatment they know will help in the long run.
Joint pain crops up, too. Some days the soreness keeps folks from work or regular chores. Vision changes take a toll as well; blurred sight or a sense that things look a little different can show up. Dry eyes, sometimes redness — no one enjoys any of these. Health workers pay close attention, since eye damage could grow permanent if ignored. Doctors check in frequently and suggest regular eye exams.
Not every reaction stays mild. One problem that stands out: low white blood cell counts or low platelets. The body relies on those cells to fight infections and to stop easy bleeding. I’ve heard stories of people developing unexplained bruises or feeling run down, then finding out they have dropped blood counts. These problems sometimes call for extra blood tests or changing the medication plan entirely.
Allergies pop up for a few folks, too. Skin rashes, fever, and sometimes swelling worry both patients and doctors. Occasionally, these allergic reactions ramp up, leading to more serious symptoms. Sharp chest pain, trouble breathing, swelling of the tongue or face — any of these need quick action and a fast visit to the emergency room.
Rifabutin also likes to interact with other medicines — not in a friendly way. People with HIV, for example, often juggle a handful of prescriptions. Rifabutin can make other treatments less effective, or increase side effects from other pills. Checking a person’s full medication list really does matter. Even supplements or herbal remedies might change how rifabutin works or break down in the body.
All side effects deserve honest conversation. If you’re on rifabutin, tracking your daily experience becomes as important as lab work. Tell your doctor about new bruises, fevers, vision changes, or stomach troubles that won’t quit. Nobody should have to tough it out alone or wonder if what they’re feeling is normal or not.
Screening before starting rifabutin gives a head start. Checking blood counts and kidney health can catch risks early. Throughout treatment, regular follow-up brings peace of mind. Health professionals and patients need to work like a team — adjustments happen, and all voices count. Reporting side effects makes care safer for everyone who comes next. Real stories and up-to-date science both shape how health care works best.
Starting on rifabutin feels serious because most people meet this medicine through a straightforward diagnosis — usually tuberculosis or another tricky infection that likes to hide inside the body. Pharmacy shelves don’t display it with over-the-counter allergy tablets. Rifabutin has a specific place in fighting slow-growing bugs, especially for folks with weaker immune defenses. Getting the most from rifabutin takes more than just picking up your prescription; it’s about matching your daily life to a reliable plan and being real with your doctor and yourself.
Plenty of people ask whether to swallow rifabutin before or after meals. Studies lean toward taking it either on an empty stomach or with a light snack if your belly rebels, since food can shift how quickly your body absorbs the drug. Crushing tablets or mixing them into beverages isn’t the best idea unless your doctor gives a clear thumbs-up. Each dose should come around the same time every day. Digestion, work schedules, family routines — all those do a dance, but missing a dose risks starting a losing battle against bacteria that learn to fight back.
Every medicine throws its own curveballs. Rifabutin likes to color anything from sweat to urine a kind of reddish-orange. It’s harmless but surprises many folks. Stomach troubles show up for some, and now and then, skin rashes or eye pain get noticed. Liver checks sometimes join the routine, especially for people with a long road ahead. I’ve learned not to shove odd feelings aside. If you notice jaundice, new fevers, or serious aches, that’s not the time for guesswork — call your doctor. Transparent conversations protect you, and sometimes they mean pausing your medicine or changing dose.
Antibiotics, especially rifabutin, teach us a lesson in patience. It’s easy to feel better after a few days and think about cutting your regimen short. That’s a big mistake. Tuberculosis bacteria, or other culprits, don’t quit that easily. Stopping early can mean a new, tougher infection. Some folks even help create drug-resistant bacteria, making future treatments riskier for the whole community. Sticking to your course speaks to respect for your own health and your neighbors’ well-being.
People face enough confusion reading prescription bottles, but rifabutin loves to mix things up. If someone takes antiretroviral drugs, birth control, antifungals, or blood thinners, rifabutin can either weaken them or amplify side effects. These combinations can shift the safety and power of your treatment. If your doctor or pharmacist wants a full medication list, bring every bottle or take photos. Open dialogue means catching problems early and dodging side effects that never had to show up.
I’ve seen people make calendars, set alarms, tape sticky notes on the fridge, or recruit friends to nudge them. Forgetting doesn’t make you careless — life just gets busy. Any missed dose throws off your fighting chance against infection, so whatever system sticks with you, use it. Pharmacists with decades of experience often suggest blending new routines into daily life, tying dose times to meals or tooth brushing. Those small changes keep rifabutin on your side instead of working against you.
Nurses, doctors, and pharmacists carry stories of patients who thrived because they made their routines as important as the medicine itself. Rifabutin only wins battles when paired with honest follow-through. It’s worth the inconvenience, every time.
Doctors often turn to rifabutin for fighting infections like tuberculosis, especially when patients live with HIV. People get excited about new options, but what gets lost in the shuffle are the headaches it can bring if you add other medicines into the mix. Rifabutin doesn’t travel alone through the body. Instead, it uses a family of liver enzymes—the same ones many other pills depend on to break down and clear out drugs. Putting rifabutin into a crowded medicine cabinet can set off chemical traffic jams.
Certain medicines get broken down faster because rifabutin revs up those liver enzymes. Blood thinners like warfarin, some antiretrovirals, birth control pills, antifungals like fluconazole, and immune suppressants like tacrolimus—these all get affected. The body chews through them more quickly, so a dose that used to work gets too weak. Some people find themselves fighting old infections that come roaring back, or noticing birth control slip-ups because hormones dropped off sooner than expected.
Other times, rifabutin goes the opposite way if it meets certain drugs—especially some HIV meds. Protease inhibitors, for instance, slow down those same liver enzymes, letting rifabutin hang around longer. Instead of getting rid of it in a day, your body holds onto rifabutin like an awkward guest who won’t leave. Then you see side effects: sore joints, a low white blood cell count, or even orange sweat that stains the sheets.
Pharmacists and prescribers spend hours checking lists and asking questions before handing over rifabutin. I remember one patient with HIV and tuberculosis on a handful of pills. Every dose meant double-checking labs and symptoms, since one wrong combination led his liver to throw up red flags for weeks. He wasn’t alone. Guidelines point out these pitfalls, but paper checklists didn’t always match the chaotic reality in real people’s lives. Missed refills, herbal teas, or unscheduled antibiotics all tossed extra chances for interactions. It’s no exaggeration—studies in journals like The Lancet have reported real harm from rifabutin-drug interactions, including failures in HIV suppression and flares of transplant rejection.
Managing these risks starts with a full snapshot of what someone is taking. It sounds simple, but some patients forget to mention supplements, over-the-counter cold medicines, or old fashioned home remedies. Digital health records offer help, yet not every pharmacy has updated lists from every doctor. Bringing along a current med list and reading medication guides helps.
Clinicians need to stay curious and humble, reaching out to infectious disease specialists or pharmacists when they spot trouble. Clinical trial data and drug interaction databases fill in the scientific details, but real life requires patience and fresh thinking every single time. Dosing adjustments, regular lab tests, and honest talks between patient and provider make a difference. No one should have to choose between fighting infection and running into a new medical crisis. Rifabutin works well, but only with teamwork and honest communication, guided by scientific research and grounded experience.
Pregnant and breastfeeding mothers know that almost everything they put in their bodies can affect their babies. With any medication, from pain relievers to antibiotics, the natural first stop is a doctor, hoping for reassurance. Rifabutin stands out because it treats serious infections like tuberculosis and MAC (Mycobacterium avium complex)—infections that don’t wait for safer times. When health hangs in the balance, unanswered questions about drug safety can weigh heavily.
Evidence on rifabutin and pregnancy safety still feels thin. Most drug warnings around pregnancy exist for a reason; babies in the womb are sensitive, and serious studies rarely include pregnant women for ethical reasons. According to the FDA, rifabutin sits under a “Category B” rating. This means studies in animals didn’t show direct harm to developing fetuses, but controlled human data is scarce. In science classrooms and at hospital bedsides, that gap grabs attention. Animal testing only travels so far before results start to break down—how a pregnant rabbit reacts isn’t always how a human would.
Some tuberculosis medicines pose known dangers during pregnancy, so comparing them side by side gives clues. I’ve heard a few infectious disease specialists say they sometimes favor rifabutin when alternatives like rifampin trigger stronger warnings. Fact is, when the infection’s risk outweighs the doubts, many clinicians look for the least harmful option. Every pregnancy proves a little unique, and doctors weigh risks with mothers on a case-by-case basis.
Most mothers want to breastfeed if they can, so drug safety during this stage sparks concern, too. Rifabutin gets into breast milk; research detects the medicine in small amounts, but whether that matters in a big way hasn’t been sorted out yet. No large group of infants exposed through breast milk has been followed for long periods, so doctors and families are left with best guesses. Reports haven’t shown clear harm in breastfed babies whose mothers took rifabutin, but the data pool is shallow. For some women—including those with HIV—treating certain infections takes priority, and stopping therapy could do more harm than good for both mother and baby.
I’ve seen new moms stare at pill bottles, weighing every possible risk, while infection looms in the background. Here, doctors can make a difference—by helping families talk through benefits, potential dangers, and signs to watch for. While researchers need better studies, real-world treatment still comes down to communication and careful monitoring. Government agencies and public health experts could prioritize research on medications like rifabutin, aiming for clearer answers. Until stronger evidence arrives, families face tough decisions, relying on trusted medical judgment and honest discussion.
Staying healthy during pregnancy and breastfeeding protects two lives, not just one. Medicines like rifabutin aren’t picked lightly, and as stronger research develops, mothers and babies deserve clear, reassuring answers.
| Names | |
| Preferred IUPAC name | (1S,11Z,21S)-21-(4-Aminopiperazin-1-yl)-5,15,17,23-tetrahydroxy-23-methoxy-1,3,13,20-tetramethyl-6,11,18,25-tetraoxo-2,7,12,19,24-pentaazapentacyclo[18.2.2.1²,⁵.1⁸,¹¹.0¹⁴,¹⁹]pentacosa-8,10,14-trien-22-yl acetate |
| Other names |
Ansamycin LM 427 Mycobutin |
| Pronunciation | /ˌrɪfəˈbjuːtɪn/ |
| Identifiers | |
| CAS Number | [72559-06-9] |
| 3D model (JSmol) | `3D model (JSmol)` string for Rifabutin: ``` CC1=C(C2=C(C=C1)C(=O)NC3=CC=CC=C23)CN4CC(CC4)C(=O)NC5CC(C(C(O5)C)OC)OC(=O)C6=CC=CC=C6 ``` |
| Beilstein Reference | 120181 |
| ChEBI | CHEBI:45086 |
| ChEMBL | CHEMBL1433 |
| ChemSpider | 54645 |
| DrugBank | DB00615 |
| ECHA InfoCard | 13babf7c-7d50-41f1-994a-3127ff6c426b |
| EC Number | EC 2.3.1.203 |
| Gmelin Reference | 78616 |
| KEGG | D08424 |
| MeSH | D016895 |
| PubChem CID | 5381226 |
| RTECS number | VZ6090000 |
| UNII | KC2Z327Y9D |
| UN number | UN3249 |
| Properties | |
| Chemical formula | C46H62N4O4 |
| Molar mass | 847.0 g/mol |
| Appearance | Rifabutin occurs as a red-violet crystalline powder. |
| Odor | Odorless |
| Density | 0.99 g/cm3 |
| Solubility in water | Insoluble in water |
| log P | 1.62 |
| Vapor pressure | 9.3E-20 mmHg |
| Acidity (pKa) | 7.9 |
| Basicity (pKb) | Basicity (pKb) of Rifabutin: **5.57** |
| Magnetic susceptibility (χ) | -7.8e-6 cm³/mol |
| Refractive index (nD) | 1.684 |
| Dipole moment | 4.67 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 785.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -8662 kJ/mol |
| Pharmacology | |
| ATC code | J04AB04 |
| Hazards | |
| Main hazards | May cause cancer; harmful if swallowed, inhaled, or absorbed through skin; causes eye, skin, and respiratory irritation |
| GHS labelling | GHS07, GHS08 |
| Pictograms | Rx; Or; Tab; Cap |
| Signal word | Warning |
| Hazard statements | Hazard statements: May cause an allergic skin reaction. Causes serious eye irritation. May cause respiratory irritation. |
| Precautionary statements | Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Keep out of reach of children. |
| Flash point | > 243.9 °C |
| Autoignition temperature | > 410 °C |
| LD50 (median dose) | LD50 (median dose): Mouse, oral: 2,000 mg/kg |
| NIOSH | UU9275000 |
| PEL (Permissible) | PEL: Not established |
| REL (Recommended) | 300 mg once daily |
| IDLH (Immediate danger) | Not listed |
| Related compounds | |
| Related compounds |
Rifampicin Rifapentine Rifaximin Rifalazil |
